Monty Pal, MD
Dr. Pal is co-director of the Kidney Cancer Program at City of Hope and head of the kidney and bladder cancer disease team at the institution.
Articles by Monty Pal, MD
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
The panel shares how they treat frontline papillary kidney cancer.
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
The panel compares three TKI/IO treatment combinations.
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
A panel discusses 4 frontline RCC treatment options.
670 Madison Ave.
Manalapan, NJ 07726